VANFLYTA®
quizartinib tablets
26.5 mg | 17.7 mg

FOR ELIGIBLE ADULTS WITH NEWLY DIAGNOSED FLT3-ITD+ AML

VANFLYTA—Talking About Your Care

Taking care of yourself or managing someone else's health can have hurdles and come with a lot of questions.

When talking with your doctor, you may not know where to start. To help you and your loved ones, we have created this guide that you can take with you to your next appointment.

Please read the VANFLYTA Medication Guide, and use this Discussion Guide to help you talk with your healthcare team and get the information you need about your treatment journey with VANFLYTA.

Important Safety Information

What is VANFLYTA?

VANFLYTA is a prescription medicine used in combination with certain chemotherapy medicines and alone as maintenance therapy to treat adults with newly diagnosed acute myeloid leukemia (AML) with a FLT3-ITD mutation.

Your healthcare provider will perform a test to make sure that VANFLYTA is right for you.

VANFLYTA is not for use alone as maintenance therapy after a hematopoietic stem cell transplant.

It is not known if VANFLYTA is safe and effective in children.

Please see additional Important Safety Information on pages 6-7 of this brochure, and click here for Full Prescribing Information, including Boxed WARNINGS, and Medication Guide.

Learning About VANFLYTA

- What is VANFLYTA?
- How does VANFLYTA work?
- How is VANFLYTA given?
- How was VANFLYTA studied?
- How is VANFLYTA different from other treatments?

Important Safety Information

What is the most important information I should know about VANFLYTA® (quizartinib)?

VANFLYTA may cause serious side effects, including:

- **Changes in the electrical activity of your heart called QT prolongation, torsades de pointes, and your heart stopping (cardiac arrest).** QT prolongation can cause irregular heartbeats that can be life-threatening or lead to death. Your healthcare provider will check the electrical activity of your heart with a test called an electrocardiogram (ECG) and will also do blood tests to check your potassium and magnesium levels before and during treatment with VANFLYTA. Tell your healthcare provider right away if you have an irregular heartbeat or feel dizzy, lightheaded, or faint, or have diarrhea or vomiting.

Please see additional Important Safety Information on pages 6-7 of this brochure, and click here for Full Prescribing Information, including Boxed WARNINGS, and Medication Guide.

VANFLYTA®
quizartinib tablets
26.5 mg | 17.7 mg

Getting Started with VANFLYTA

- **Are there other treatments, like chemotherapy, that I need to take while I am on VANFLYTA?**

- **How often will I receive VANFLYTA?**

- **How will I know if treatment with VANFLYTA is working?**

- **What if I forget to take a dose of VANFLYTA?**

- **Is a bone marrow transplant an option for me? What can I expect if I receive one?**

Important Safety Information

What is the most important information I should know about VANFLYTA® (quizartinib)? (cont.)

VANFLYTA is available only through a restricted program called the VANFLYTA Risk Evaluation and Mitigation Strategy (REMS) due to the risk of QT prolongation, torsades de pointes, and cardiac arrest.

You will receive a VANFLYTA Patient Wallet Card from your healthcare provider. **Carry the VANFLYTA Patient Wallet Card with you at all times and show it to all of your healthcare providers.** The VANFLYTA Patient Wallet Card lists signs and symptoms of QT prolongation and torsades de pointes.

Get medical help right away if you develop any of the signs and symptoms listed on the VANFLYTA Patient Wallet Card. You may need to be treated in a hospital.

Please see additional Important Safety Information on pages 6-7 of this brochure, and click here for Full Prescribing Information, including Boxed WARNINGS, and Medication Guide.

VANFLYTA®
quizartinib tablets
26.5 mg | 17.7 mg

Additional Questions About VANFLYTA

- What are the most common side effects that people experience with VANFLYTA?
- What are the possible serious side effects with VANFLYTA?
- How often will I be monitored when I receive VANFLYTA?
- Is there financial support available to help with VANFLYTA?
- Are there any support groups that you'd recommend?
- Are there any additional resources available for patients that are on treatment with VANFLYTA?

Important Safety Information

What is the most important information I should know about VANFLYTA® (quizartinib)? (cont.)

See **"What are the possible side effects of VANFLYTA?"** for more information about side effects.

Please see additional Important Safety Information on pages 6-7 of this brochure, and click here for Full Prescribing Information, including Boxed WARNINGS, and Medication Guide.

VANFLYTA®
quizartinib tablets
26.5 mg | 17.7 mg

Please write down any additional questions or information here:

Important Safety Information

What is the most important information I should know about VANFLYTA® (quizartinib)? (cont.)

What is VANFLYTA?

VANFLYTA is a prescription medicine used in combination with certain chemotherapy medicines and alone as maintenance therapy to treat adults with newly diagnosed acute myeloid leukemia (AML) with a FLT3-ITD mutation.

Your healthcare provider will perform a test to make sure that VANFLYTA is right for you.

Please see additional Important Safety Information on pages 6-7 of this brochure, and click here for Full Prescribing Information, including Boxed WARNINGS, and Medication Guide.

VANFLYTA®
quizartinib tablets
26.5 mg | 17.7 mg

Important Safety Information

What is the most important information I should know about VANFLYTA® (quizartinib)?

VANFLYTA may cause serious side effects, including:

- **Changes in the electrical activity of your heart called QT prolongation, torsades de pointes, and your heart stopping (cardiac arrest).** QT prolongation can cause irregular heartbeats that can be life-threatening or lead to death. Your healthcare provider will check the electrical activity of your heart with a test called an electrocardiogram (ECG) and will also do blood tests to check your potassium and magnesium levels before and during treatment with VANFLYTA. Tell your healthcare provider right away if you have an irregular heartbeat or feel dizzy, lightheaded, or faint, or have diarrhea or vomiting.

VANFLYTA is available only through a restricted program called the VANFLYTA Risk Evaluation and Mitigation Strategy (REMS) due to the risk of QT prolongation, torsades de pointes, and cardiac arrest.

You will receive a VANFLYTA Patient Wallet Card from your healthcare provider. **Carry the VANFLYTA Patient Wallet Card with you at all times and show it to all of your healthcare providers.** The VANFLYTA Patient Wallet Card lists signs and symptoms of QT prolongation and torsades de pointes.

Get medical help right away if you develop any of the signs and symptoms listed on the VANFLYTA Patient Wallet Card. You may need to be treated in a hospital.

See **"What are the possible side effects of VANFLYTA?"** for more information about side effects.

What is VANFLYTA?

VANFLYTA is a prescription medicine used in combination with certain chemotherapy medicines and alone as maintenance therapy to treat adults with newly diagnosed acute myeloid leukemia (AML) with a FLT3-ITD mutation.

Your healthcare provider will perform a test to make sure that VANFLYTA is right for you.

VANFLYTA is not for use alone as maintenance therapy after a hematopoietic stem cell transplant.

It is not known if VANFLYTA is safe and effective in children.

Who should not take VANFLYTA?

Do not take VANFLYTA if you have very low potassium, very low magnesium, long QT syndrome, or a history of ventricular arrhythmias or torsades de pointes.

Before you take VANFLYTA, tell your healthcare provider about all of your medical conditions, including if you:

- have any heart problems.
- have low blood levels of potassium or magnesium.
- are pregnant or plan to become pregnant. VANFLYTA can harm your unborn baby. Tell your healthcare provider right away if you become pregnant or think you may be pregnant during treatment with VANFLYTA.
  - If you are able to become pregnant, your healthcare provider will perform a pregnancy test within 7 days before you start treatment with VANFLYTA.
  - **Females** who are able to become pregnant should use effective birth control (contraception) during treatment with VANFLYTA and for 7 months after the last dose of VANFLYTA.
  - **Males** who have female partners who are able to become pregnant should use effective birth control during treatment with VANFLYTA and for 4 months after the last dose of VANFLYTA.
  - Talk to your healthcare provider about birth control methods you can use during this time.
- are breastfeeding or plan to breastfeed. It is not known if VANFLYTA passes into your breast milk. Do not breastfeed during treatment with VANFLYTA and for 1 month after the last dose of VANFLYTA.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. VANFLYTA and other medicines may affect each other causing side effects.

Especially tell your healthcare provider if you take St. John's wort. You should not take St. John's wort during treatment with VANFLYTA.

VANFLYTA®
quizartinib tablets
26.5 mg | 17.7 mg

Please see Full Prescribing Information, including Boxed WARNINGS, and Medication Guide.

Important Safety Information

What are the possible side effects of VANFLYTA?

VANFLYTA may cause serious side effects, including:

- See **"What is the most important information I should know about VANFLYTA?"**

The most common side effects of VANFLYTA include:

- low white blood cell counts
- changes in levels of electrolytes in the blood
- changes in liver function tests
- low white blood cell counts with fever
- diarrhea
- mouth sores
- nausea
- stomach (abdominal) pain
- serious infection throughout the body and organs (sepsis)
- headache
- vomiting
- upper respiratory tract infections
- low platelet counts
- decreased appetite
- fungal infections
- nosebleed
- herpesvirus infections
- trouble sleeping
- abnormal electrocardiogram (QT prolongation)
- upset stomach
- low red blood cell counts (anemia)
- eye irritation

Your healthcare provider will do blood tests and ECGs before you start and during treatment with VANFLYTA. Your healthcare provider may tell you to decrease your dose, temporarily stop, or permanently stop taking VANFLYTA if you develop certain side effects during treatment with VANFLYTA.

VANFLYTA may cause fertility problems in females and males, which may affect your ability to have children. Talk to your healthcare provider if you have concerns about fertility.

These are not all the possible side effects of VANFLYTA. Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088.

How should I take VANFLYTA?

- **Take VANFLYTA exactly as your healthcare provider tells you to.** Do not change your dose or stop taking VANFLYTA unless your healthcare provider tells you to.
- Take VANFLYTA by mouth 1 time a day at about the same time each day.
- Take VANFLYTA with or without food.
- Swallow VANFLYTA tablets whole. Do not cut, crush, or chew the tablets.
- If you miss a dose of VANFLYTA or did not take it at your usual time, take your dose as soon as possible on the same day. Take your next dose at your usual time on the next day. Do not take 2 doses on the same day to make up for a missed dose.
- If you vomit after taking a dose of VANFLYTA, do not take another dose. Take your next dose at your usual time the next day.

Please see Full Prescribing Information, including Boxed WARNINGS, and Medication Guide.

Learn more about this type of cancer called FLT3-ITD+ AML

VISIT VANFLYTA.COM →

OR SCAN

Daiichi-Sankyo

VANFLYTA® quizartinib tablets
26.5 mg | 17.7 mg